Prospective, single-arm, and phase II study of the first-line treatment of extensive-stage small-cell lung cancer by the sequential PD-L1 inhibitor Adebrelimab following chemotherapy

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 8a91686642043600c167b32931518449723fb57a
First added on: Oct 10, 2026